Positives: Globally recognised assays bringing significant awareness to BIT's compound library. Big Pharma are looking, and potentially assessing BIT as a takeover target
Negatives: BIT working on a new series of designed and synthesised compounds (the first lot not good enough?). Screening of new serious of compounds expected to conclude only by end 2020 (Toooo slow! bring on BIT225)
Unknowns: Potency level of currently screened compounds?
BIT Price at posting:
11.5¢ Sentiment: Hold Disclosure: Held
